Scott Carmer Named as CEO of Orgenesis North America

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Scott Carmer Named as CEO of Orgenesis North America

GERMANTOWN, MD--(Marketwired - Aug 4, 2014) - Orgenesis Inc . ( OTCQB : ORGS ), a leader in the emerging fields of cellular therapy and re-generative medicine, today announced the appointment of industry veteran Scott Carmer as CEO of the company's North American subsidiary. Carmer has more than 25 years of diverse industry experience within both pharmaceutical and biotech companies.

Orgenesis is a pioneer in the field of "cellular trans-differentiation," a technology that has potential to regenerate glucose-responsive insulin production and restore glycemic homeostasis for patients suffering from various insulin-dependent disorders. By transforming a patient's own liver cells into new insulin producing cells, Orgenesis hopes to develop a breakthrough therapy for people living with Type 1 Diabetes. In his new role, Carmer will oversee the Orgenesis drug development and commercialization strategy in North America, focusing on the near-term initiation of Phase I and Phase II clinical trials in the United States.

"As the father of a child who is living with Type 1 Diabetes," Carmer said. "I am personally motivated to help bring the innovative science pioneered by the Orgenesis team into the clinic. The technology of cellular trans-differentiation, discovered in the research labs of Prof. Sarah Ferber, has established pre-clinical Proof-of-Principle that human adult liver cells can successfully be transformed into glucose responsive and functionally mature insulin producing cells. I am honored and excited to be a part of this company and its cause. It's extremely motivating to be working with a team of people dedicated to curing Type 1 Diabetes as we know it today."

Before joining Orgenesis, Carmer led the US Specialty Care Division of AstraZeneca, and had responsibility for the company's portfolio of specialty care biopharmaceutical products. Prior to his role at AZ, he served as Executive Vice President, Commercial Operations of MedImmune (which was acquired by AstraZeneca). Previous to his roles at AZ/MedImmune, Carmer was Vice President, Rheumatology Sales & Marketing for Genentech, where he was responsible for the US launches of Rituxan and ACTEMRA in Rheumatoid Arthritis. He joined Genetech from Amgen, Inc., where he last held the role of Global Therapeutic Area Head for Bone and Metabolic Disorders, and was responsible for global development and commercialization strategies for denosumab (Xgeva and Prolia). Carmer began his career at GSK, where he held various positions of increasing responsibility in the areas of sales, marketing, strategic pricing and business development.

"Scott is a natural leader with an established track record of successfully building and leading teams. His vast commercialization experience in the field of biologics -- from early clinical development to launch -- will be a tremendous asset to Orgenesis as we work to quickly transition our technology from research into P1 clinical trials," said Vered Caplan, chairperson and CEO of Orgenesis. "He has a proven ability to work in close partnership with research, clinical, regulatory and manufacturing functions to successfully bring complex biologics to market. Scott is a solutions-oriented, creative thinker, and we are excited to have him as a part of our team."

About Orgenesis, Inc. Orgenesis is a development stage company that is committed to curing Type 1 Diabetes. In pursuit of this goal, the company is developing a novel technology that combines cellular therapy and regenerative medicine. Through a proprietary biologic process called 'cellular trans-differentiation,' Orgenesis has proven that, when exposed ex vivo to certain pancreatic transcription factors and in specific sequence, human adult liver cells can be transformed into fully functional, beta cell-like insulin producing cells (IPCs). After ex vivo expansion, the IPCs are reinfused via the portal vein. In pre-clinical models of Type 1 Diabetes (Non-Obese Diabetic mice), the re-introduced IPCs remain in the liver, effectively respond to glucose challenge and successfully maintain glycemic homeostasis. In the same NOD model, the implanted IPCs were not subject to auto-immune attack or cellular ablation. Orgenesis plans to initiate P1/2 trials in the next 12-16 months. For more information visit: www.orgenesis.com .

Notice Regarding Forward-Looking Statements This news release contains "forward-looking statements" which are not purely historical. Such forward-looking statements include, among other things, the expectations of management that our regeneration technology can be developed as therapeutic treatment for diabetes which could, if successful, mean the end of diabetes as we know it; that we will initiate Phase I and Phase II clinical trials in the United States in the near-term; that we can quickly transition our technology from research into P1 clinical trials. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits Orgenesis will obtain from them. Actual results could differ from those projected in any forward-looking statements due to numerous factors, including, among others, the potential failure of development candidates to advance through preclinical studies or demonstrate safety and efficacy in clinical testing; the ability to pass clinical trials so as to move on to the next phase; our ability to retain key employees; our ability to finance development and operations; our ability to satisfy the rigorous regulatory requirements for new medical procedures; and competitors may develop better or cheaper alternatives to our products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Investors should refer to the risk factors disclosure outlined in our periodic reports filed from time-to-time with the Securities and Exchange Commission.

Company Contact: Vered Caplan Chairperson & CEO + 972-54 4301 034 Vered.C@orgenesis.com Media Contact: Tim Rush Springboard5 (801) 208-1100 tim.rush@springboard5.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Paratus on the Move: Seagems JV Under the Microscope

Updated Category News Views 194

What's Cooking with Paratus Energy? Paratus Energy Services Ltd. (ticker: PLSV) just threw us a curveball, announcing a strategic review of its participation in the Seagems joint venture. Now, before you get too jazzed about ticker talk—hold your horses. No one's making any promises about transactions just yet. The decision's still hanging in the balance, even as they...

Continue Reading
Avelo Tests Loyalty Math With WeSalute Fare Discounts

Updated Category News Views 287

Airline discounts can look like generosity until the load factor starts talking back. Avelo Airlines has joined WeSalute with fare discounts for active-duty military members, veterans, first responders, nurses, medical professionals, public servants, teachers and eligible family members. It is a sensible move for a young carrier built around smaller airports and lower...

Continue Reading
Chaos Zero Nightmare's Award Is a Useful Signal for Games

Updated Category News Views 232

A story award can be easy to sneer at until a live-service game earns one across three markets. Smilegate's Chaos Zero Nightmare, a dark fantasy roguelike RPG developed by Super Creative, was named Best Story in Google Play's Best of 2026 awards for Taiwan, Hong Kong and Macau. That is not a sales figure, not a profit disclosure, and certainly not proof that a hit has...

Continue Reading
Sectra's RSNA AI Pitch Centers on Workflow, Not Hype

Updated Category News Views 45

Radiology has heard enough grand AI promises to fill a hospital basement, which makes Sectra's RSNA 2026 message refreshingly grounded. The Swedish imaging IT and cybersecurity company is putting its weight behind the unglamorous part of adoption: fitting AI into the daily diagnostic machinery without handing clinicians another awkward system to babysit. That is where...

Continue Reading
Sokin’s UAE License Turns Expansion Into Real Payments Plumbing

Updated Category News Views 23

Dubai expansion headlines are cheap; regulated local money movement is not. That is why Sokin’s newly approved Dubai Financial Services Authority license deserves more than the usual fintech applause line. The company has paired that approval with AED accounts, local payment rails, a One Za’abeel office and a plan to double its UAE staff over the next year. None of...

Continue Reading
MAXHUB's Canon Office Test Puts Hybrid Work on Trial

Updated Category News Views 81

Thirty-nine devices scattered through a new Hong Kong office may not sound earth-shaking, but this is how workplace technology actually earns its keep: not under trade-show lights, but when somebody is late to a meeting in another time zone and the room has to work anyway. MAXHUB and Canon Hong Kong have launched the first officially delivered Co-Create 100 project...

Continue Reading
Envision and Tai Tam Put 45 MW Wind Bet to Work in Vietnam

Updated Category News Views 92

A wind site averaging 6.5 meters per second can look unremarkable on a map, yet that is precisely where equipment choices start separating serious developers from brochure merchants. Envision Energy and Vietnam's Tai Tam Group are taking that test on with the 45 MW Phuoc Dan wind project in Khanh Hoa Province. The arrangement follows five years of cooperation, but the...

Continue Reading
FULC, DSGR and OPCH Deals Draw Fresh Shareholder Scrutiny

Updated Category News Views 94

Three proposed transactions have drawn the kind of legal glare that makes shareholders sit up and check the fine print twice. On November 18, 2026, Halper Sadeh LLC said it was investigating deals involving Fulcrum Therapeutics, Distribution Solutions Group, and Option Care Health for possible federal securities-law violations or fiduciary-duty breaches. That is not a...

Continue Reading
Litmus Gets $475 Million as Music Rights Mature Further

Updated Category News Views 0

Music royalties just got another serious pile of institutional money, and Litmus is holding the shovel. The company announced roughly $475 million of new capital commitments from Carlyle and investment funds managed by KKR, a notable vote of confidence in a platform that did not even exist before 2022. This is not some celebrity vanity vehicle buying a famous chorus and...

Continue Reading
STORMER LAT Targets Sewer Crews' Costly Access Delays

Updated Category News Views 65

A buried cleanout can turn a simple sewer inspection into a scheduling circus. That unglamorous headache is exactly where FIBERSCOPE is aiming its new STORMER LAT Lateral Launch Camera System, announced November 17, 2026. This is not some flashy consumer gadget hunting for attention; it is field equipment built around a painfully ordinary municipal problem: crews often...

Continue Reading

Top 5 Most Recently Viewed Articles

TCL SunPower Global Teams Up with Energia Italia for Solar Expansion

Updated Category News Views 313

TCL SunPower Global and Energia Italia Join Forces TCL SunPower Global is thrilled to unveil a new strategic partnership with Energia Italia, designed to significantly enhance the availability of advanced solar technology. As a renowned distributor in the residential and commercial solar markets, Energia Italia will take on the responsibility of providing Italian...

Continue Reading
AHAM Challenges Colorado's Appliance Labeling in Court

Updated Category News Views 200

AHAM Takes Legal Action Against Appliance Labeling Law The Association of Home Appliance Manufacturers (AHAM) has filed a federal lawsuit in response to a new appliance labeling law in Colorado. This law specifically mandates that gas stoves display a warning label concerning alleged health risks. AHAM alleges that this directive infringes upon First Amendment rights,...

Continue Reading
Impact BioMedical Inc. Sets Price for Its Initial Public Offering

Updated Category News Views 63

Impact BioMedical Inc. Pricing for Initial Public Offering Announced Impact BioMedical Inc. (NYSE: IBO) has officially revealed the pricing details for its initial public offering, establishing itself as a significant presence in the healthcare and wellness sectors. The company plans to offer 1,500,000 shares of its common stock at a public offering price of $3.00 per...

Continue Reading
Local Bounti Navigates NYSE Compliance Notice, Eyes Growth

Updated Category News Views 151

Local Bounti Faces NYSE Compliance Challenge Local Bounti Corporation (NYSE: LOCL), a pioneer in innovative indoor agriculture, has recently received an important notice from the New York Stock Exchange (NYSE). The notice highlights that the company is currently not meeting certain listing standards set by the NYSE. This notification pertains to the Minimum Market...

Continue Reading
SCWorx Expands Partnership: Three-Year Renewal and Growth

Updated Category News Views 154

SCWorx Strengthens Healthcare Partnerships with Renewed Agreement New York, NY — In a significant move, SCWorx Corp. (NASDAQ: WORX), known for its innovative healthcare data management solutions, has successfully renewed its agreement with a vital healthcare partner for another three years. This decision marks a substantial endorsement of the value SCWorx delivers, as...

Continue Reading